 |
|
The Role of Cervical Lymphadenectomy After Aggressive Concomitant Chemoradiotherapy
The Feasibility of Selective Neck Dissection
Kerstin M. Stenson, MD;
Danial J. Haraf, MD;
Harold Pelzer, MD;
Wendy Recant, MD;
Merrill S. Kies, MD;
Ralph R. Weichselbaum, MD;
Everett E. Vokes, MD
Arch Otolaryngol Head Neck Surg. 2000;126:950-956.
Objectives To evaluate the necessity, technical feasibility, and complication rate of neck dissection performed on patients with head and neck cancer after 5 cycles of concomitant chemoradiotherapy (CRT) and to justify a selective neck dissection (SND) approach and define the optimal timing of post-CRT neck dissection.
Design and Setting Retrospective analysis in an academic university medical center.
Patients Sixty-nine eligible patients with advanced (stage III and IV) head and neck cancer who have undergone 1 of 4 CRT protocols. Patients ranged in age from 36 to 75 years, and surgical procedures were performed over a 4-year period. Follow-up ranged from 6 to 64 months.
Intervention Neck dissection (most commonly unilateral SND) performed within 5 to 17 weeks after CRT completion.
Main Outcome Measures Complication rate and incidence of positive pathology (viable cancer) in pathologic neck dissection specimens.
Results Seven (10%) of 69 patients developed wound healing complications, 4 (6%) of whom required surgical intervention for ultimate closure. There were no wound infections. Other complications occurred in 11 (16%) of 69 patients and included need for tracheotomy, nerve transection and paresis, and permanent hypocalcemia. Twenty-four (35%) of 69 patients revealed microscopic residual disease. Ten (50%) of 20 patients with N3 neck disease had positive pathology, whereas 14 (36%) of 39 patients with N2 disease had viable carcinoma in the dissection specimen (P = .09 by  2 analysis). There was no significant relation between radiologic complete response or partial response and residual microscopic cancer. In 1 patient, disease recurred in the neck after dissection. Mean follow-up time was 30.3 months.
Conclusions (1) Neck dissection for patients with N2 or greater neck disease after CRT is necessary to eradicate residual disease. (2) The complication rate of SND after CRT with hyperfractionated radiotherapy is low. (3) SNDs are technically feasible when performed within the "window" between the acute and chronic CRT injury (4-12 weeks). (4) SNDs, rather than more radical procedures, appear to be therapeutically appropriate in this group of patients because of the low incidence of disease recurrence in the neck.
From the Department of Surgery, Section of Otolaryngology–Head and Neck Surgery (Dr Stenson), the Departments of Radiation Oncology and Biophysics (Dr Haraf), Pathology (Dr Recant), Radiation and Cellular Oncology and Biophysics (Dr Weichselbaum), and Medicine, Section of Hematology/Oncology (Dr Vokes), University of Chicago, Chicago, Ill; and the Departments of Otolaryngology/Head and Neck Surgery (Dr Pelzer) and Medicine, Section of Hematology/Oncology (Dr Kies), Northwestern University, Chicago.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Otolaryngology–Head & Neck Surgery Reader's Choice: Continuing Medical Education
Arch Otolaryngol Head Neck Surg. 2000;126(8):1043-1044.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Early Prediction of Response to Chemoradiotherapy for Head and Neck Cancer: Reliability of Restaging With Combined Positron Emission Tomography and Computed Tomography
Malone et al.
Arch Otolaryngol Head Neck Surg 2009;135:1119-1125.
ABSTRACT
| FULL TEXT
Neck Dissection Planning Based on Postchemoradiation Computed Tomography in Patients With Head and Neck Cancer
Langerman et al.
Arch Otolaryngol Head Neck Surg 2009;135:876-880.
ABSTRACT
| FULL TEXT
Ability of Positron Emission Tomography to Detect Residual Neck Node Disease in Patients With Head and Neck Squamous Cell Carcinoma After Definitive Chemoradiotherapy
Tan et al.
Arch Otolaryngol Head Neck Surg 2007;133:435-440.
ABSTRACT
| FULL TEXT
Superselective Neck Dissection After Chemoradiation: Feasibility Based on Clinical and Pathologic Comparisons
Robbins et al.
Arch Otolaryngol Head Neck Surg 2007;133:486-489.
ABSTRACT
| FULL TEXT
Concurrent Chemoradiotherapy for Locally Advanced, Nonmetastatic, Squamous Carcinoma of the Head and Neck: Consensus, Controversy, and Conundrum
Brizel and Esclamado
JCO 2006;24:2612-2617.
ABSTRACT
| FULL TEXT
Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer.
Goguen et al.
Arch Otolaryngol Head Neck Surg 2006;132:526-531.
ABSTRACT
| FULL TEXT
Postradiotherapy Neck Dissection for Lymph Node-Positive Head and Neck Cancer: The Use of Computed Tomography to Manage the Neck
Liauw et al.
JCO 2006;24:1421-1427.
ABSTRACT
| FULL TEXT
Multiagent Concurrent Chemoradiotherapy for Locoregionally Advanced Squamous Cell Head and Neck Cancer: Mature Results From a Single Institution
Adelstein et al.
JCO 2006;24:1064-1071.
ABSTRACT
| FULL TEXT
Effectiveness of Superselective and Selective Neck Dissection for Advanced Nodal Metastases After Chemoradiation
Robbins et al.
Arch Otolaryngol Head Neck Surg 2005;131:965-969.
ABSTRACT
| FULL TEXT
The Role of Computed Tomographic Scans in the Management of the N-Positive Neck in Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy
Velazquez et al.
Arch Otolaryngol Head Neck Surg 2004;130:74-77.
ABSTRACT
| FULL TEXT
Induction Chemotherapy followed by Concomitant TFHX Chemoradiotherapy with Reduced Dose Radiation in Advanced Head and Neck Cancer
Haraf et al.
Clin. Cancer Res. 2003;9:5936-5943.
ABSTRACT
| FULL TEXT
Weekly Carboplatin and Paclitaxel Followed by Concomitant Paclitaxel, Fluorouracil, and Hydroxyurea Chemoradiotherapy: Curative and Organ-Preserving Therapy for Advanced Head and Neck Cancer
Vokes et al.
JCO 2003;21:320-326.
ABSTRACT
| FULL TEXT
Recurrence Rates After Selective Neck Dissection in the N0 Irradiated Neck
Fritz et al.
Arch Otolaryngol Head Neck Surg 2002;128:292-295.
ABSTRACT
| FULL TEXT
|
